Replimune Announces BLA Acceptance and Priority Review for RP1 for the Treatment in Advanced Melanoma
PDUFA action date of July 22, 2025, with priority review January 21, 2025 08:00 ET| Source: Replimune Group Inc WOBURN,…
Copyright © 2014-2022 - AIM at Melanoma Foundation. All rights reserved. Website by RED ZEPHYR DESIGN